BamSEC and AlphaSense Join Forces
Learn More

C4 Therapeutics Inc.

NASDAQ: CCCC    
Share price (12/20/24): $3.95    
Market cap (12/20/24): $279 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K/A 13 pages Redacted Redacted
12/34/56
EX-10.1
from 8-K 13 pages Redacted Redacted
12/34/56
EX-10.1
from 8-K 2 pages Material contract
12/34/56
EX-10.1
from 10-Q 60 pages Material contract
12/34/56
EX-10.19
from 10-K 7 pages Material contract
12/34/56
EX-10.18
from 10-K 111 pages Execution Version Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Information That Was Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark “[***]”. License and Collaboration Agreement by and Between C4 Therapeutics, Inc. and Merck Sharp & Dohme LLC
12/34/56
EX-10.2
from 8-K 39 pages Stock Purchase Agreement Between C4 Therapeutics, Inc., Betta Investment (Hong Kong) Limited and Betta Pharmaceuticals Co., Ltd. Dated as of May 29, 2023
12/34/56
EX-10.1
from 8-K 71 pages License and Collaboration Agreement by and Between C4 Therapeutics, Inc., and Betta Pharmaceuticals Co., Ltd. May 29, 2023
12/34/56
EX-10.2
from 10-K 43 pages C4 Therapeutics, Inc. 2020 Stock Option and Incentive Plan
12/34/56
EX-10.1
from 8-K 36 pages Third Amendment to Lease
12/34/56
EX-10.13
from 10-K 9 pages [***] Certain Information in This Document Has Been Omitted From This Exhibit Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. First Amendment to Amended and Restated License Agreement
12/34/56
EX-10.11
from 10-K 4 pages [***] Certain Information in This Document Has Been Omitted From This Exhibit Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Amendment No. 1 to Collaborative Research and License Agreement
12/34/56
EX-10.3
from S-1/A 6 pages C4 Therapeutics, Inc. 2020 Employee Stock Purchase Plan
12/34/56
EX-10.2
from S-1/A 47 pages C4 Therapeutics, Inc. 2020 Stock Option and Incentive Plan
12/34/56
EX-10.14
from S-1 85 pages Material contract
12/34/56
EX-10.13
from S-1 101 pages Certain Confidential Portions of This Exhibit Have Been Omitted and Replaced With “[***]”. Such Identified Information Has Been Excluded From This Exhibit Because It Is (I) Not Material and (II) Would Likely Cause Competitive Harm to the Company if Disclosed
12/34/56
EX-10.12
from S-1 48 pages Collaboration and License Agreement
12/34/56
EX-10.11
from S-1 87 pages [***] Certain Information in This Document Has Been Omitted From This Exhibit Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed
12/34/56
EX-10.10
from S-1 77 pages [***] Certain Information in This Document Has Been Omitted From This Exhibit Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed
12/34/56
EX-10.9
from S-1 13 pages C4 Therapeutics, Inc. Consultation Agreement
12/34/56